Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06841315 · ClinicalTrials.gov registry record · Phase 1
A Varegacestat Hepatic Impairment Study
A Phase 1 study, sponsored by Immunome.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06841315 is a Phase 1 study that has completed, run by Immunome. The registered enrollment target is 35 participants.
The verdict
NCT06841315, a Phase 1 study, has completed, sponsored by Immunome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
Interventions
- DRUG varegacestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2026-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06841315
The ClinicalTrials.gov registry entry for NCT06841315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which varegacestat is the first listed.
NCT06841315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06841315 about?
NCT06841315 is a clinical study titled "A Varegacestat Hepatic Impairment Study". This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
What is the current status of trial NCT06841315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2025-03-07. Estimated completion is 2026-03-06.
What interventions are being tested in trial NCT06841315?
The interventions under investigation include: varegacestat (DRUG).
Who is sponsoring clinical trial NCT06841315?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.